Results 191 to 200 of about 8,209 (210)

Upadacitinib

Reactions Weekly, 2023
  +12 more sources

Upadacitinib: First Approval

Drugs, 2019
Upadacitinib (Rinvoq™), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis. In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of ...
Sean, Duggan, Susan J, Keam
openaire   +2 more sources

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Lancet, The, 2021
Andrew Blauvelt, Chia Yu Chu, H Chih-Ho Hong   +2 more
exaly  

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Lancet, The, 2022
Edward V Loftus, Remo Panaccione
exaly  

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2021
Kristian Reich, Marjolein de Bruin-Weller, Thomas Bieber   +2 more
exaly  

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

RMD Open, 2023
Gerd R Burmester, Stanley B Cohen, Kevin L Winthrop   +2 more
exaly  

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Annals of the Rheumatic Diseases, 2021
Stanley B Cohen, Ronald F Van Vollenhoven, Kevin L Winthrop   +2 more
exaly  

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results

Journal of Allergy and Clinical Immunology, 2022
Jonathan I Silverberg, Marjolein de Bruin-Weller, Thomas Bieber   +2 more
exaly  

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

RMD Open, 2022
Roy M Fleischmann, Louis Bessette, Patrick Durez   +2 more
exaly  

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial

Arthritis and Rheumatology, 2020
Tsutomu Takeuchi, Maureen Rischmueller, Ricardo Blanco   +2 more
exaly